This led to the thought that targeting the PI3K pathway could restore the sensitivity of breast cancer cells to chemotherapy drugs, leading to PEGGY and BELLE-4 trials as discussed in detail below [34,35]. Here, PIK3CA is linked to breast carcinoma.